Questcor Pharmaceuticals still in an uptrend but meeting resistance at $35.00

May 6th, 2013 – Comment

Currently the MACD and the RSI are indicating that buyers a still accumulating this stock.

About the Author

Lou Schizas is an equities analyst, investor, entrepreneur, professor and television and radio personality – and a true believer in the happiness-inspiring powers of capitalism.

Read the author's full profile.

Further Research

Read more about Pharmaceuticals.


Hi Lou,

I enjoy your column, and value your advice.
Could you comment on, Questcor Pharma.


Hey John,

Thanks for the assignment and your support. Both are very much appreciated! Questcor Pharmaceuticals Inc. (QCOR NASDAQ) is a one trick pony stock.  Most of its revenue is derived from the sale of Acthar gel which is used to treat nearly twenty conditions including multiple sclerosis, and infant spasms. The stock took a hit last fall as the company’s promotional activities were put under review and there were reports that a major insurance company had revised its thoughts on Acthar. The stock has been in recovery mode  doubling the 52-week low of $17.25 it hit in September of 2012.

A review of the charts will indicate  if the aggressive bounce off the lows have more to give.



The three-year chart has one outstanding feature that is very noticeable. The advance off the September lows appears to have formed an ascending triangle which suggests that there is more to this up move. Also of note is the resistance that has formed at $35.00 and after that $40.00 is the next barrier that has to be overcome.  Another pattern visible on the chart are the buy signals that were generated by the MACD and the RSI in October of 2012 as buyers took control of the market.







The six-month chart provides a close-up of the nascent start of a golden cross. The MACD and the RSI both signalled a move higher in April as the stock tested support at $27.00 generating a 26.5% return in less than a month. A nice get for those who acted on the opportunity. If you like the QCOR story you want to keep in mind that it has one horse in the race. Anything happens to Acthar it happens to shareholders worse. Currently the MACD and the RSI are indicating that buyers a still accumulating this stock. But that doesn’t meant the situation can’t change at any moment.

Make it a profitable day and happy capitalism!

Categories: Pharmaceuticals
Content © Relentless Economics - Charts courtesy - Employees Entrance - Optimization Media